We aimed to compare the long-term clinical outcomes of patients treated with sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES) for coronary bifurcation lesions.
Background
There are limited data regarding comparisons of SES and PES for the treatment of bifurcation lesions.
Methods
Patients who received percutaneous coronary intervention for non-left main bifurcation lesions were enrolled from 16 centers in Korea between January 2004 and June 2006. We compared major adverse cardiac events (MACE [cardiac death, myocardial infarction, or target lesion revascularization]) between the SES and PES groups in patients overall and in 407 patient pairs generated by propensity-score matching.
Results
We evaluated 1,033 patients with bifurcation lesions treated with SES and 562 patients treated with PES. The median follow-up duration was 22 months. Treatment with SES was associated with a lower incidence of MACE (hazard ratio [HR] : 0.53, 95% confidence interval [CI] : 0.32 to 0.89, p Ͻ 0.01) and target lesion revascularization (HR: 0.55, 95% CI: 0.31 to 0.97, p ϭ 0.02), but not of cardiac death (HR: 2.77, 95% CI: 0.40 to 18.99, p ϭ 0.62) and cardiac death or myocardial infarction (HR: 0.97, 95% CI: 0.38 to 2.49, p ϭ 0.94). After propensity-score matching, patients with SES still had fewer MACE and target lesion revascularization incidences than did patients with PES (HR: 0.52, 95% CI: 0.30 to 0.91, p ϭ 0.02, and HR: 0.48, 95% CI: 0.25 to 0.91, p ϭ 0.02, respectively). There was no significant difference in the occurrences of stent thrombosis between the groups (0.7% vs. 0.7%, p ϭ 0.94).
Conclusions
In patients with bifurcation lesions, the use of SES resulted in better long-term outcomes than did the use of PES, primarily by decreasing the rate of repeat revascularization. Sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) have been shown to markedly improve angiographic and clinical outcomes after percutaneous coronary intervention (PCI) when compared to bare-metal stents (1, 2) . A number of studies comparing the efficacy and safety of SES and PES have been performed in a variety of lesion subsets and clinical settings (3-7), but there are limited data comparing these 2 stents in the treatment of bifurcation lesions. Although 3 previous studies compared the clinical outcomes of patients treated with SES or PES for bifurcation lesions, these studies were small and underpowered, and the data from these studies are conflicting (8 -10) . Therefore, we sought to compare the long-term clinical outcomes after implantation of the 2 most widely available drug-eluting stent (DES) platforms for coronary bifurcation lesions using data from a dedicated, large, multicenter real-world registry.
Methods
Study population. The COBIS (Coronary Bifurcation Stent) registry was a retrospective multicenter registry dedicated to bifurcation lesion PCI with DES. It included data on consecutive patients from 16 major coronary intervention centers in Korea. Inclusion criteria were: 1) coronary bifurcation lesions treated solely with at least 1 DES between January 2004 and June 2006; and 2) main vessel diameter Ն2.5 mm and side branch diameter Ն2.0 mm. Exclusion criteria were the presence of cardiogenic shock, ST-segment elevation acute myocardial infarction (MI) within 48 h, life expectancy Ͻ1 year, or left main bifurcation. This registry was sponsored by the Korean Society of Interventional Cardiology. The local institutional review board at each hospital approved this study and waived the requirement for informed consent for access to the each institutional PCI registry.
To compare SES and PES, we selected patients in the COBIS registry database treated solely with SES or PES. Bifurcation lesions were classified according to the Medina classification, in which the proximal main vessel, distal main vessel, and side branch components of the bifurcation are each assigned a score of 1 or 0 depending on the presence or absence of Ͼ50% stenosis (11) . Percutaneous coronary intervention. All patients were administered loading doses of aspirin (300 mg) and clopidogrel (300 to 600 mg) or ticlopidine (500 mg) before the coronary intervention unless they had previously received these antiplatelet medications. Anticoagulation therapy during PCI was performed according to current practice guidelines by the Korean Society of Interventional Cardiology. The treatment strategy, stenting techniques, and selection of DES type were all left to the operator's discretion. Decisions to use glycoprotein IIb/IIIa receptor inhibitors or intravascular ultrasound (IVUS) were also made by the individual operators. Aspirin was continued indefinitely. The duration of thienopyridine treatment was also at the operator's discretion.
Follow-up and end points. Clinical, angiographic, procedural, and outcome data were collected with the use of a web-based reporting system. Additional information was obtained by further inquiry into medical records or telephone contact, if necessary. All baseline and procedural cine coronary angiograms were reviewed and qualitatively analyzed at the angiographic core laboratory in the Cardiac and Vascular Center, Samsung Medical Center, Seoul, Korea. Medina classification type 1.1.1, 1.0.1, and 0.1.1 lesions were defined as true bifurcation lesions.
The study end point was the occurrence of a major adverse cardiac event (MACE) during follow-up, defined as a composite of: 1) cardiac death; 2) MI; or 3) target lesion revascularization (TLR). All deaths were considered cardiac unless a definite noncardiac cause could be established. An MI was defined as elevated cardiac enzymes (troponin or myocardial band fraction of creatine kinase) more than the upper limit of the normal value with ischemic symptoms or electrocardiography findings indicative of ischemia that was not related to the index procedure. TLR was defined as repeat PCI of the lesion within 5 mm of stent deployment or bypass graft surgery of the target vessel. Target vessel revascularization (TVR) was repeat revascularization of the target vessel by PCI or bypass graft surgery. Periprocedural enzyme elevation was defined as a rise in creatine kinase-myocardial band Ն3 times the upper normal limit after the index procedure (12) . The periprocedural period includes the first 48 h after PCI, and periprocedural enzyme elevation was not considered as MACE in our study. Stent thrombosis (ST) was assessed based on the definitions of the Academic Research Consortium as definite, probable, or possible stent thrombosis (12) . The timing of ST was classified as early (within 1 month after index procedure), late (between 1 month and 1 year), or very late (after 1 year). All outcome data reported from the participating centers were reviewed by an independent clinical event adjudicating committee. Statistical analyses. Differences between the groups of patients receiving SES and PES in baseline characteristics were compared using the t test or Wilcoxon rank-sum test for continuous variables, and the chi-square test or Fisher's exact test for categorical variables, as appropriate. Survival curves were constructed using Kaplan-Meier estimates and were compared with the log-rank test. Covariates statistically significant on univariate analysis and/or those clinically relevant were considered as candidate variables in the multivariate models. Adjusted hazard rates were compared by means of Cox regression with age, sex, acute coronary syndrome, diabetes mellitus, true bifurcation, stenting techniques, final kissing balloon inflation, use of IVUS, type of stent used, stent diameter, and total stent length. We also included use of clopidogrel as a time-dependent covariate (assessed at 1, 3, 6, and 12 months) in the model. To reduce treatment-selection bias for stent type and potential confounding, we performed rigorous adjustment for baseline characteristics of patients using propensity score. The propensity scores were estimated using multiple logistic-regression analysis. A full nonparsimonious model was developed that included all variables listed in Tables 1 and 2 . The discrimination and calibration abilities of the propensity-score model were assessed by means of the c-statistic and the Hosmer-Lemeshow statistic. Cox regression analysis using pairs matched by a greedy 5¡1 matching algorithm was also performed. We assessed the balance in baseline covariates between the 2 groups in a propensity score-matched cohort. Continuous variables were compared with a paired t test or the Wilcoxon signed-rank test, as appropriate, and categorical variables were compared with the McNemar's or Bowker's test of symmetry, as appropriate. In the propensity score-matched population, a reduction in the risk of outcome was compared by use of a conditional Cox regression model (13) . Cumulative incidence rates of individual clinical outcomes and composite outcomes were estimated by the Kaplan-Meier method and compared by the stratified Cox regression with clopidogrel use as a time-dependent variable. All p values are 2-tailed, and p Ͻ 0.05 was considered significant. All analyses were performed using a Statistical Analysis Software package (SAS version 9.1, SAS Institute, Cary, North Carolina).
Results
Baseline characteristics. OVERALL POPULATION. Among 1,919 patients registered, 251 patients did not fulfill the inclusion criteria by core laboratory cineangiographic analysis, and were excluded from the study. We also excluded other types of DES or mixed use of SES and PES (n ϭ 73). A total of 1,595 patients was selected in the final analysis: 1,033 patients received SES and 562 patients received PES. Baseline demographic, clinical, angiographic, and procedural characteristics of the 2 groups are shown in Tables 1  and 2 . The PES group had higher a prevalence of diabetes mellitus and acute coronary syndrome on admission. In the SES group, IVUS and final kissing balloon inflation were performed more frequently, and the diameter of side branch stents implanted was larger than that of the PES group. Other characteristics, including bifurcation site treated, Medina classification, and stenting technique, were similar in both groups. Main vessel stenting alone was primarily performed in both groups. There were no significant differences in procedural characteristics such as stent type, treatment strategy (1-stent vs. 2-stent), and use of glycoprotein IIb/IIIa inhibitors among centers. However, use of IVUS differed significantly according to the PCI volume of centers (data not shown).
PROPENSITY-MATCHED POPULATION.
After performing propensity-score matching for the entire population, a total of 407 matched pairs of patients were created (Tables 1 and  2 ). The c-statistic for the propensity score model was 0.65, which indicates good discrimination (Hosmer-Lemeshow goodness of fit, p ϭ 0.78). There were no significant differences in baseline clinical, angiographic, and procedural characteristics for the propensity-matched subjects. Fig. 1A ). Although both groups had comparable incidences of cardiac death or MI, the SES group had a significantly lower incidence of TLR and TVR ( Of patients who had definite or probable thrombosis, the SES group had 6 on dual antiplatelet therapy and 1 on aspirin only, and the PES group had 3 patients on dual antiplatelet therapy and 1 on aspirin only. The incidence of definite or probable ST was not significantly different between the groups (0.7% vs. 0.7%, p ϭ 0.99).
There were 54 events with a median follow-up of 22 months in the matched patients. With respect to the primary composite outcome, SES was still associated with a significantly better outcome in the matched cohort of patients than was PES (Table 3 , Fig. 2A) . Although there were no differences Angiographic and Procedural Characteristics Data are presented as mean Ϯ SD or n (%). LAD ϭ left anterior descending artery; LCX ϭ left circumflex artery; OM ϭ obtuse marginal branch; RCA ϭ right coronary artery; other abbreviations as in Table 1 .
between the 2 groups in the incidence of death or MI, patients with SES had a significantly lower rate of TLR and TVR compared with patients who had PES (Table 3 , Fig.  2B ). In multivariate analysis, SES was associated with significant reductions in the primary composite outcome and TLR (Table 3 ). The incidence of periprocedural enzyme elevation and definite or probable ST was similar in the 2 groups (17.4% in the SES group vs. 16.5% in the PES group, p ϭ 0.71; and 1.0% in the SES group vs. 0.5% in the PES group, p ϭ 0.41, respectively). Subgroup analysis. To determine whether the superior outcomes for SES observed in the overall population were consistent, we calculated the unadjusted hazard ratio for MACE in various complex subgroups (Fig. 3) . The rate of MACE was numerically lower in the SES group than in the PES group in all subgroups, although statistical significance was not found in patients with diabetes, non-true bifurcation, or those treated with 2-stent techniques. As shown in Figure 3 , there were no significant interactions between the type of stent and MACE among the 5 subgroups.
Discussion
In the present study, we compared long-term clinical outcomes after implantation of SES or PES for the treatment of coronary bifurcation lesions in the largest dedicated bifurcation registry data to date. The main findings of this study were: 1) SES implantation was associated with a lower incidence of MACE than was PES implantation, driven mainly by the lower incidence of TLR; and 2) there was no difference in the rates of cardiac death, MI, or ST between the 2 groups. Coronary bifurcation lesions are 1 of the most challenging lesion subsets and are known to have lower angiographic success rates and a higher risk of procedural complications with a greater restenosis rate than are nonbifurcation le- sions, even in the DES era (14, 15) . Considering that bifurcation lesions are frequent in real-world practice (16) , it is very important to investigate which DES is most effective in treating bifurcation lesions. However, there are limited data regarding comparisons among DES in bifurcation lesions. Although 3 previous studies were performed comparing the clinical outcomes of patients treated with SES versus PES for bifurcation lesions, all of these studies were actually underpowered for the determination of clinical end points. Moreover, the data from these studies were conflicting, with 2 studies demonstrating significantly lower TLR rates for SES compared with PES (8, 9) and the other showing no differences between the 2 stents (10). Therefore, we compared the long-term clinical outcomes after PCI with the 2 most widely available DES, SES, and PES, using the COBIS registry. This nationwide multicenter registry is solely dedicated to bifurcation lesions treated with DES; it is the largest registry for coronary bifurcation lesions to date. Broad indication may make it possible to reflect real-world practice and outcomes regarding PCI on bifurcation lesions. All baseline and procedural cine coronary angiograms were reviewed at the angiographic core laboratory and patients were thoroughly monitored.
In this study, we demonstrated that SES was more effective in improving long-term outcomes than was PES, primarily by decreasing repeat revascularization. Patients with PES have shown comparable clinical outcomes to those with SES in several studies (5-7), but the latter DES may be superior to the former in complex lesion subsets (17) (18) (19) . Considering the complexity of bifurcation lesions, 
Figure 3 Comparative Unadjusted Hazard Ratios of MACE for Subgroups
ACS ϭ acute coronary syndrome; CIϭ confidence interval; MACE ϭ major adverse cardiac events; PES ϭ paclitaxel-eluting stent(s); SES ϭ sirolimus-eluting stent(s).
